Table 1.

Adverse events reported in the included studies

Study ID	Number of participants	Methods to monitor adverse events	Blinding		Comment on AE
			Participants	Clinicians
Min 1975	48	No comment	unclear	unclear	No comment
Pongpanich 1973	7	No comment	unclear	unclear	No comment
Sumarmo 1982	47	No comment	blinded	unclear	No comment
Tassniyom 1993	32	Physical examination, blood test No specific recording of adverse events	blinded	blinded	No significant difference between treatment and control groups in occurrence of fever after shock, pneumonia, convulsion, cardiac arrest, pulmonary haemorrhage, and positive hemo‐culture No specific comments on adverse events
Kularatne 2009	100	Clinical signs recorded at baseline: mean axillary temperature, headache, nausea, flush, pulse rate, blood pressure Laboratory tests: hematocrit and white blood cell count (day 0 to 4) No specific recording of adverse events	blinded	unclear	No comment
Shashidhara 2013	61	No comment	not blinded	not blinded	No comment
Tam 2012	150	Prospective adverse events reporting active surveillance of patient‐reported symptoms and laboratory results Laboratory tests: full blood count and random glucose level daily, with a fasting glucose test performed if the random glucose test showed a high level Biochemistry and coagulation profiles, heparan sulfate (HS) at day 0 (enrolment) day, days 5 to 6, and at follow‐up 2 to 3 weeks after discharge Recording: by trained study physicians using standardized structured case report form (severity, relatedness of study drugs). daily recording throughout the disease course Reporting: regularly to the Data and Safety Monitoring Board (DSMB).	blinded	blinded	Transient hyperglycaemia in a small number of cases, but no significant clinical or virological adverse events detected
Villar 2009	87	Recording: systematic evaluation of adverse events during and after drug administration and monitoring Reporting: to an independent committee to evaluate the safety and efficacy by interim analysis. These reports are available immediately, and the final report after 30 days (from protocol).	blinded	blinded	No adverse events reported. Adverse events reported to the committee were defined as fatal serious adverse effects, life‐threatening or clinically significant